Eurofins Successfully Prices New €600m 7-Year Senior Unsecured Bonds
August 30 2023 - 10:55AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA, rated Baa3/stable by Moody’s and
BBB-/stable by Fitch, “Eurofins”), a global leader in
bioanalytical testing, announces that it has successfully raised
€600m in its latest senior unsecured Euro-denominated public bond
issuance (the “Bonds”). The Bonds have a 7-year maturity
(due on 6 September 2030) and will bear an annual fixed rate coupon
of 4.75%. The transaction was well received and was more than 2.7x
over-subscribed.
The proceeds of those bonds will be used to fund Eurofins’
general corporate purposes, including the refinancing of the
outstanding €448m Fixed Rate Bonds (ISIN: XS1651444140) due in July
2024.
Comment from the CEO, Dr Gilles Martin: “We are very
pleased with the results of our latest public bond issuance, which
demonstrates again the confidence of Eurofins’ investors in our
long-term value creation strategy while maintaining a sound capital
structure.”
The Bonds will be listed from their issue date (6 September
2023) on the regulated market of the Luxembourg stock exchange
(ISIN XS2676883114). The Bonds are not registered under the US
Securities Act of 1933 as amended (the “Securities Act”) and may
not be offered or sold in (i) the United States (as such term is
defined in Regulation S under the Securities Act) unless registered
under the Securities Act or pursuant to an exemption from such
registration nor (ii) in any other jurisdiction where it is
unlawful to do so.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins network of companies
believes that it is the global leader in food, environment,
pharmaceutical and cosmetic product testing and in discovery
pharmacology, forensics, advanced material sciences and agroscience
contract research services. It is also one of the market leaders in
certain testing and laboratory services for genomics, and in the
support of clinical studies, as well as in biopharma contract
development and manufacturing. It also has a rapidly developing
presence in highly specialised and molecular clinical diagnostic
testing and in-vitro diagnostic products.
With over 62,000 staff across a decentralised and
entrepreneurial network of ca. 900 laboratories in 61 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230830863663/en/
For more information, please visit www.eurofins.com or
contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024